Samantha Keogh, Emily N Larsen, Felicity Edwards, Makrina Totsika, Nicole Marsh, Patrick N A Harris, Kevin B Laupland
{"title":"Speciation of coagulase-negative staphylococci: A cohort study on clinical relevance and outcomes.","authors":"Samantha Keogh, Emily N Larsen, Felicity Edwards, Makrina Totsika, Nicole Marsh, Patrick N A Harris, Kevin B Laupland","doi":"10.1016/j.idh.2025.04.001","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Coagulase-negative staphylococci (CoNS) are common causes of bloodstream infections (BSI), but species-specific epidemiology is under-researched. This study aimed to examine the occurrence, clinical features, and outcomes of CoNS BSI in a large Australian population.</p><p><strong>Methods: </strong>All incidents of CoNS BSI in the Queensland Health system (2000-2019) were included.</p><p><strong>Results: </strong>Among 4046 CoNS BSI cases, 3353 were monomicrobial, with S. epidermidis (n = 1665), S. haemolyticus (n = 224), S. hominis (n = 220), S. capitis (n = 185), S. lugdunensis (n = 57), S. warneri (n = 47), and other species (n = 38). In 27% of cases, CoNS isolates were not assigned to species. Significant differences in age, onset classification, co-morbidities, and flucloxacillin resistance were observed across species. S. epidermidis, S. haemolyticus. S. capitis were predominantly hospital-onset, while S. lugdunensis was community-associated. The cohort had Charlson scores indicating high co-morbidity, with malignancy common among S. haemolyticus patients. Most speciated isolates of CoNS demonstrated resistance to flucloxacillin (2224/2827; 79%). The 30-day mortality rate was higher for polymicrobial (14%) vs. monomicrobial BSI (11%), p = 0.024. Mortality varied by species and was highest for S. lugdunensis (22%).</p><p><strong>Conclusions: </strong>These findings underscore the value of species-level identification in managing CoNS BSIs, particularly in cases with clinical signs and symptoms, to support antimicrobial stewardship.</p>","PeriodicalId":94040,"journal":{"name":"Infection, disease & health","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection, disease & health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.idh.2025.04.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Coagulase-negative staphylococci (CoNS) are common causes of bloodstream infections (BSI), but species-specific epidemiology is under-researched. This study aimed to examine the occurrence, clinical features, and outcomes of CoNS BSI in a large Australian population.
Methods: All incidents of CoNS BSI in the Queensland Health system (2000-2019) were included.
Results: Among 4046 CoNS BSI cases, 3353 were monomicrobial, with S. epidermidis (n = 1665), S. haemolyticus (n = 224), S. hominis (n = 220), S. capitis (n = 185), S. lugdunensis (n = 57), S. warneri (n = 47), and other species (n = 38). In 27% of cases, CoNS isolates were not assigned to species. Significant differences in age, onset classification, co-morbidities, and flucloxacillin resistance were observed across species. S. epidermidis, S. haemolyticus. S. capitis were predominantly hospital-onset, while S. lugdunensis was community-associated. The cohort had Charlson scores indicating high co-morbidity, with malignancy common among S. haemolyticus patients. Most speciated isolates of CoNS demonstrated resistance to flucloxacillin (2224/2827; 79%). The 30-day mortality rate was higher for polymicrobial (14%) vs. monomicrobial BSI (11%), p = 0.024. Mortality varied by species and was highest for S. lugdunensis (22%).
Conclusions: These findings underscore the value of species-level identification in managing CoNS BSIs, particularly in cases with clinical signs and symptoms, to support antimicrobial stewardship.